Provided by Tiger Fintech (Singapore) Pte. Ltd.

LAVA Therapeutics N.V.

1.37
+0.05003.79%
Volume:91.54K
Turnover:125.87K
Market Cap:36.03M
PE:-1.34
High:1.40
Open:1.35
Low:1.35
Close:1.32
Loading ...

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

GlobeNewswire
·
10 Jan

LAVA Therapeutics to Transition to U.S. Domestic Issuer

TIPRANKS
·
02 Jan

Leerink Partners Downgrades LAVA Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2 From $11

MT Newswires Live
·
12 Dec 2024

LAVA Therapeutics Nv : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $2 From $11

THOMSON REUTERS
·
12 Dec 2024

LAVA Therapeutics Nv : Leerink Partners Cuts to Market Perform From Outperform

THOMSON REUTERS
·
12 Dec 2024

Lava Therapeutics Cut to Market Perform From Market Outperform by JMP Securities

Dow Jones
·
12 Dec 2024

JMP Securities Downgrades LAVA Therapeutics NV to Market Perform From Market Outperform

MT Newswires Live
·
11 Dec 2024

JMP Securities downgrades LAVA Therapeutics (LVTX) to a Hold

TIPRANKS
·
11 Dec 2024

LAVA Therapeutics NV reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
10 Dec 2024

LAVA Therapeutics Q3 2024 GAAP EPS $(0.46) Misses $(0.33) Estimate

Benzinga
·
10 Dec 2024

LAVA Therapeutics Nv: Qtrly Loss per Share $0.46

THOMSON REUTERS
·
10 Dec 2024

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension Into 2027

THOMSON REUTERS
·
10 Dec 2024

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

GlobeNewswire
·
10 Dec 2024

LAVA Therapeutics NV expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
29 Nov 2024

LAVA Therapeutics NV expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
22 Nov 2024

LAVA Therapeutics NV expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
12 Nov 2024